What is PrIMAVeRa?
Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance (PrIMAVeRA) seeks to develop mathematical models and an epidemiological repository to assess the impact of vaccines and monoclonal antibodies (mAbs) on antimicrobial resistance (AMR), one of the top ten threats to global health as determined by the World Health Organization (WHO).
This five-year project (01 November 2021 - 31 October 2026) brings together global leaders in the fields of computational and mathematical modelling, epidemiology, statistics, health economics, microbiology, database management, data science, monoclonal antibody research, and regulatory procedure.
How is PrIMAVeRa funded?
PrIMAVeRA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 101034420. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (The European Federation of Pharmaceutical Industries and Associations).
It is coordinated by the European Vaccine Initiative (Germany), with support from Professor Marc Bonten of the University Medical Center Utrecht (Netherlands) as scientific coordinator and GlaxoSmithKline as industry lead. It involves 19 partners across the EU, the UK and Russia, including 16 academic institutions and small and medium enterprises (SME), as well as GlaxoSmithKline, Pfizer and Janssen as industry partners.
Project scope and structure:
The ultimate goal of PrIMAVeRa is to develop comprehensive mathematical models to predict the impact of vaccines and mAbs on the reduction of AMR, thereby enabling decision-makers to prioritise the most promising new vaccines and mAbs. A sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including models, beyond the duration of the PrIMAVeRa project.